NovaBay Pharmaceuticals, Inc. (NBY)

$0.2633

+0.01 (+5.32%)
Rating:
Recommendation:
Buy
Symbol NBY
Price $0.2633
Beta 3.315
Volume Avg. 0.61M
Market Cap 13.854M
Shares () -
52 Week Range 0.17-0.77
1y Target Est -
DCF Unlevered NBY DCF ->
DCF Levered NBY LDCF ->
ROE -36.44% Strong Sell
ROA -17.81% Sell
Operating Margin -
Debt / Equity 39.72% Neutral
P/E -
P/B 0.74 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NBY news


Mr. Justin Hall
Healthcare
Biotechnology
American Stock Exchange

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.